Neurology
🇺🇸 FDA Page 5FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 49–60 of 63 articles
Kyverna's Miv-cel Shows Breakthrough Results in Stiff Person Syndrome Trial, Potentially First Approved Treatment
Ractigen Therapeutics RAG-17 Shows 81% Reduction in ALS Biomarker in Phase I Trial
Pasithea Therapeutics' PAS-004 Receives FDA Rare Pediatric Disease Designation for Neurofibromatosis Type 1 Treatment
Clearmind Medicine CMND-100 Meets Primary Safety Endpoint in Alcohol Use Disorder Trial
Breakthrough Therapy Designations Drive Neurological Drug Innovation in US
Lundbeck's VYEPTI Shows Improvement in Migraine-Related Cognitive Symptoms in Real-World INFUSE Study
UCB Acquires Neurona Therapeutics for NRTX-1001 Epilepsy Cell Therapy in $XXX Million Deal
argenx VYVGART Shows Promise Across Multiple Myasthenia Gravis Subtypes in New AAN 2026 Clinical Data
Sedogen Receives U.S. Patent for Diazoxide Treatment of Prader-Willi Syndrome Behavioral Symptoms
Nexalin Technology Advances FDA Strategy for Alzheimer's Treatment Following U.S. and China Leadership Meetings
Cala Receives FDA Clearance for Next-Generation kIQ Plus Wearable Device for Essential Tremor and Parkinson's Disease
SynuSight Biotech's SST001 Alpha-Synuclein PET Tracer Receives NMPA Approval for Phase I Clinical Trial